Current Challenges With MDD Treatment Options
February 2nd 2023Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.
Prevalence of Hypothyroidism in a Commercially Insured US Population: Results by Region
January 24th 2023An expert in hypothyroidism management reviews key prevalence data examined across US regions and examined by treatment type from a recent poster presentation highlighting the prevalence of hypothyroidism in a commercially insured US population.
Prevalence of Hypothyroidism in a Commercially Insured US Population: Age and Gender Results
January 24th 2023Dr Alex Tessnow discusses the key prevalence data stratified by gender and age within a longitudinal, retrospective, database study examining the prevalence of hypothyroidism in a commercially insured US population.
Prevalence of Hypothyroidism in a Commercially Insured US Population: Overview and Trial Design
January 24th 2023Alex Tessnow M.D. provides a brief overview of the study rationale and design of the recently presented poster highlighting the prevalence of hypothyroidism in a commercially insured US population.